posterpresentation
Description

Title: 1667 - Immunohistochemical Study of O-GlcNAcylation in Adenoid Cystic Carcinoma

Authors:

LORDJIE MARR MORILLA (Presenter)
Khon Kaen University

Ponlatham Chaiyarit, Khon Kaen University
Ajiravudh Subarnbhesaj, Khon Kaen University
Rajda Noisombut , Khon Kaen University
Poramaporn Klanrit, Khon Kaen University

Abstract:

Objectives: O-GlcNAcylation is a form of glycosylation, which is considered as a post-translational modification that has been known to have a role in tumour formation. Different patterns of expression levels of O-GlcNAcylation have been observed in various tumours, including breast, lung, and colon tumours. It has been suggested that increased O-GlcNAcylation seems to be a characteristic of tumour cells. However, no prior studies have investigated expression levels of O-GlcNAcylation in salivary gland tumours (SGTs). Therefore, this study aimed to investigate expression levels of O-GlcNAcylation in adenoid cystic carcinoma (AdCC) which is one of the common malignant SGTs as compared with normal salivary glands.

Methods: Immunohistochemical expression levels of O-GlcNAcylation were investigated in formalin-fixed and paraffin-embedded samples of 15 AdCC and 15 normal salivary glands. The expression levels were graded using semiquantitative scoring (0-4).

Results: All samples of AdCC and normal salivary glands expressed O-GlcNAcylation, but O-GlcNAcylation levels in AdCC samples were significantly elevated as compared to those in normal salivary glands (p<0.05; Fisher’s Exact Test). Noticeably, the majority of AdCC (8 samples; 53.3%) expressed O-GlcNAcylation with the immunostaining score 3 (50%-<75% positively stained cells) while the majority of normal salivary gland samples (7 cases; 46.7%) expressed O-GlcNAcylation with the immunostaining score 1 (5%-<25% positively stained cells).

Conclusions: These results suggest that O-GlcNAcylation is markedly increased in AdCC and may play a role in the pathogenesis of AdCC.

Student Presenter

Disclosure Statement:
The submitter must disclose the names of the organizations with which any author have a relationship, the nature of the relationship, and the clinical or research area involved. The following is submitted: NONE

Tags